4
Aug
2021
Sonoma Bio, Engineering T-cell Therapies for Autoimmunity, Nabs $265M Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jul
2021
Rivus Gets $35M to Alter Mitochondria for T2D, NASH, Heart Failure & More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jun
2021
F-Prime Leads $60M Bet on Adela, Scanning the Methylome for Early Signs of Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.